{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T15:58:32Z","timestamp":1790524712662,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T00:00:00Z","timestamp":1643155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Indian J Pediatr"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s12098-021-03988-y","type":"journal-article","created":{"date-parts":[[2022,1,26]],"date-time":"2022-01-26T12:02:41Z","timestamp":1643198561000},"page":"699-705","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and Safety of Combination Therapy with Tolvaptan and Furosemide in Children with Nephrotic Syndrome and Refractory Edema: A Prospective Interventional Study"],"prefix":"10.1007","volume":"89","author":[{"given":"Jitendra","family":"Meena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Hari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Bagga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,26]]},"reference":[{"key":"3988_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/j.1365-2362.1985.tb00139.x","volume":"15","author":"EB Pedersen","year":"1985","unstructured":"Pedersen EB, Danielsen H, Madsen M, Jensen T. Defective renal water excretion in nephrotic syndrome: the relationship between renal water excretion and kidney function, arginine vasopressin, angiotensin II and aldosterone in plasma before and after oral water loading. Eur J Clin Invest. 1985;15:24\u20139.","journal-title":"Eur J Clin Invest"},{"key":"3988_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5049\/EBP.2015.13.1.17","volume":"13","author":"SW Oh","year":"2015","unstructured":"Oh SW, Han SY. Loop diuretics in clinical practice. Electrolytes Blood Press. 2015;13:17\u201321.","journal-title":"Electrolytes Blood Press"},{"key":"3988_CR3","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s12098-020-03252-9","volume":"87","author":"J Meena","year":"2020","unstructured":"Meena J, Bagga A. Current perspectives in management of edema in nephrotic syndrome. Indian J Pediatr. 2020;87:633\u201340.","journal-title":"Indian J Pediatr"},{"key":"3988_CR4","doi-asserted-by":"publisher","first-page":"907","DOI":"10.2215\/CJN.04390808","volume":"4","author":"G Kapur","year":"2009","unstructured":"Kapur G, Valentini RP, Imam AA, Mattoo TK. Treatment of severe edema in children with nephrotic syndrome with diuretics alone\u2013a prospective study. Clin J Am Soc Nephrol. 2009;4:907\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3988_CR5","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/FJC.0b013e318074f934","volume":"50","author":"SE Shoaf","year":"2007","unstructured":"Shoaf SE, Bramer SL, Bricmont P, Zimmer CA. Pharmacokinetic and pharmacodynamic interaction between tolvaptan, a non-peptide AVP antagonist, and furosemide or hydrochlorothiazide. J Cardiovasc Pharmacol. 2007;50:213\u201322.","journal-title":"J Cardiovasc Pharmacol"},{"key":"3988_CR6","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00467-013-2687-1","volume":"29","author":"M Shimizu","year":"2014","unstructured":"Shimizu M, Ishikawa S, Yachi Y, et al. Tolvaptan therapy for massive edema in a patient with nephrotic syndrome. Pediatr Nephrol. 2014;29:915\u20137.","journal-title":"Pediatr Nephrol"},{"key":"3988_CR7","doi-asserted-by":"publisher","first-page":"53","DOI":"10.4103\/ijn.IJN_358_18","volume":"30","author":"J Meena","year":"2020","unstructured":"Meena J, Sinha A, Hari P, Bagga A. Therapy with the combination of tolvaptan and furosemide for refractory edema in nephrotic syndrome. Indian J Nephrol. 2020;30:53\u20135.","journal-title":"Indian J Nephrol"},{"key":"3988_CR8","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1681\/ASN.2008030287","volume":"20","author":"GJ Schwartz","year":"2009","unstructured":"Schwartz GJ, Mu\u00f1oz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629\u201337.","journal-title":"J Am Soc Nephrol"},{"key":"3988_CR9","doi-asserted-by":"crossref","unstructured":"Sakaida I, Yanase M, Kobayashi Y, Yasutake T, Okada M, Okita K. ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res. 2012;40:2381\u201393.","DOI":"10.1177\/030006051204000637"},{"key":"3988_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/ped.12590","volume":"57","author":"D Hirano","year":"2015","unstructured":"Hirano D, Kakegawa D, Yamada A, Ito A, Miwa S, Ida H. Tolvaptan in a pediatric patient with diuretic-resistant heart and kidney failure. Pediatr Int. 2015;57:183\u20135.","journal-title":"Pediatr Int"},{"key":"3988_CR11","doi-asserted-by":"crossref","unstructured":"Matsuzaki M, Hori M, Izumi T, Fukunami M. Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther. 2011;25 Suppl 1:S33\u201345.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"3988_CR12","doi-asserted-by":"crossref","unstructured":"Konstam MA, Gheorghiade M, Burnett JC Jr. et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319\u201331.","DOI":"10.1001\/jama.297.12.1319"},{"key":"3988_CR13","doi-asserted-by":"crossref","unstructured":"Ma G, Ma X, Wang G, Teng W, Hui X. Effects of tolvaptan add-on therapy in patients with acute heart failure: meta-analysis on randomised controlled trials. BMJ Open. 2019;9:e025537.","DOI":"10.1136\/bmjopen-2018-025537"},{"key":"3988_CR14","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s12876-015-0297-z","volume":"15","author":"L Yan","year":"2015","unstructured":"Yan L, Xie F, Lu J, et al. The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials. BMC Gastroenterol. 2015;15:65.","journal-title":"BMC Gastroenterol"},{"key":"3988_CR15","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1007\/s10157-013-0788-6","volume":"17","author":"T Otsuka","year":"2013","unstructured":"Otsuka T, Sakai Y, Ohno D, Murasawa T, Sato N, Tsuruoka S. The effects of tolvaptan on patients with severe chronic kidney disease complicated by congestive heart failure. Clin Exp Nephrol. 2013;17:834\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"3988_CR16","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.hlc.2017.12.013","volume":"27","author":"J Sen","year":"2018","unstructured":"Sen J, Chung E, McGill D. Tolvaptan for heart failure in chronic kidney disease patients: a systematic review and meta-analysis. Heart Lung Circ. 2018;27:928\u201339.","journal-title":"Heart Lung Circ"},{"key":"3988_CR17","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1007\/s10157-016-1379-0","volume":"21","author":"M Katsumata","year":"2017","unstructured":"Katsumata M, Hirawa N, Sumida K, et al. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure. Clin Exp Nephrol. 2017;21:858\u201365.","journal-title":"Clin Exp Nephrol"},{"key":"3988_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/AC.70.2.3073514","volume":"70","author":"A Tanaka","year":"2015","unstructured":"Tanaka A, Katsuno T, Ozaki T, et al. The efficacy of tolvaptan as a diuretic for chronic kidney disease patients. Acta Cardiol. 2015;70:217\u201323.","journal-title":"Acta Cardiol"},{"key":"3988_CR19","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.2215\/CJN.09630818","volume":"14","author":"DH Ellison","year":"2019","unstructured":"Ellison DH. Clinical Pharmacology in Diuretic Use. Clin J Am Soc Nephrol. 2019;14:1248\u201357.","journal-title":"Clin J Am Soc Nephrol"},{"key":"3988_CR20","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/nep.12348","volume":"20","author":"ES Park","year":"2015","unstructured":"Park ES, Huh Y, Kim GH. Is tolvaptan indicated for refractory oedema in nephrotic syndrome? Nephrology (Carlton). 2015;20:103\u20136.","journal-title":"Nephrology (Carlton)"},{"key":"3988_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1111\/nep.13390","volume":"23","author":"T Takada","year":"2018","unstructured":"Takada T, Masaki T, Hoshiyama A, Toki T, Kamata Y, Shichiri M. Tolvaptan alleviates excessive fluid retention of nephrotic diabetic renal failure unresponsive to furosemide. Nephrology (Carlton). 2018;23:883\u20136.","journal-title":"Nephrology (Carlton)"},{"key":"3988_CR22","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.2169\/internalmedicine.55.7133","volume":"55","author":"T Masuda","year":"2016","unstructured":"Masuda T, Murakami T, Igarashi Y, et al. Dual impact of tolvaptan on intracellular and extracellular water in chronic kidney disease patients with fluid retention. Intern Med. 2016;55:2759\u201364.","journal-title":"Intern Med"},{"key":"3988_CR23","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1007\/s00246-013-0671-y","volume":"34","author":"RB Regen","year":"2013","unstructured":"Regen RB, Gonzalez A, Zawodniak K, et al. Tolvaptan increases serum sodium in pediatric patients with heart failure. Pediatr Cardiol. 2013;34:1463\u20138.","journal-title":"Pediatr Cardiol"},{"key":"3988_CR24","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1007\/s00467-020-04530-6","volume":"35","author":"JD Delbet","year":"2020","unstructured":"Delbet JD, Parmentier C, Ulinski T. Tolvaptan therapy to treat severe hyponatremia in pediatric nephrotic syndrome. Pediatr Nephrol. 2020;35:1347\u201350.","journal-title":"Pediatr Nephrol"},{"key":"3988_CR25","doi-asserted-by":"crossref","unstructured":"Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Tolvaptan Investigators. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther. 2011;25 Suppl 1:S57\u201365.","DOI":"10.1007\/s10557-011-6349-x"},{"key":"3988_CR26","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.cardfail.2011.08.005","volume":"17","author":"JE Udelson","year":"2011","unstructured":"Udelson JE, Bilsker M, Hauptman PJ, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17:973\u201381.","journal-title":"J Card Fail"},{"key":"3988_CR27","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1159\/000481995","volume":"46","author":"N Tominaga","year":"2017","unstructured":"Tominaga N, Kida K, Inomata T, et al. Effects of tolvaptan addition to furosemide in normo- and hyponatremia patients with heart failure and chronic kidney disease stages G3b\u20135: a subanalysis of the K-STAR study. Am J Nephrol. 2017;46:417\u201326.","journal-title":"Am J Nephrol"},{"key":"3988_CR28","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1007\/s10157-017-1475-9","volume":"22","author":"S Minami","year":"2018","unstructured":"Minami S, Hamano T, Iwatani H, Mizui M, Kimura Y, Isaka Y. Tolvaptan promotes urinary excretion of sodium and urea: a retrospective cohort study. Clin Exp Nephrol. 2018;22:550\u201361.","journal-title":"Clin Exp Nephrol"},{"key":"3988_CR29","doi-asserted-by":"publisher","first-page":"F46","DOI":"10.1152\/ajprenal.2000.279.1.F46","volume":"279","author":"CA Ecelbarger","year":"2000","unstructured":"Ecelbarger CA, Kim GH, Terris J, et al. Vasopressin-mediated regulation of epithelial sodium channel abundance in rat kidney. Am J Physiol Renal Physiol. 2000;279:F46-53.","journal-title":"Am J Physiol Renal Physiol"},{"key":"3988_CR30","doi-asserted-by":"publisher","first-page":"F460","DOI":"10.1152\/ajpcell.1986.250.3.C460","volume":"250","author":"DC Merrill","year":"1986","unstructured":"Merrill DC, Cowley AW Jr. Chronic effects of vasopressin on plasma renin activity in sodium-restricted dogs. Am J Physiol. 1986;250:F460\u20139.","journal-title":"Am J Physiol"}],"container-title":["Indian Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-021-03988-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12098-021-03988-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12098-021-03988-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,17]],"date-time":"2022-06-17T05:15:57Z","timestamp":1655442957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12098-021-03988-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,26]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["3988"],"URL":"https:\/\/doi.org\/10.1007\/s12098-021-03988-y","relation":{},"ISSN":["0019-5456","0973-7693"],"issn-type":[{"value":"0019-5456","type":"print"},{"value":"0973-7693","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,26]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval for this study was obtained from the institutional ethics committee of All Institute of Medical Sciences, New Delhi (IECPG-161\/23.08.2017, RT-35\/07.09.2017) and all procedures performed in studies were in accordance with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent and assent were obtained from all individual.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}